Roche to acquire Viewics, Inc. to provide data-driven lab business analytics and add further digital capabilities along the laboratory value chain

RocheRoche (SIX: RO, ROG; OTCQX: RHHBY) has announced an agreement with Viewics, Inc., a privately held software company focused on laboratory business analytics. Under the agreement, Roche is acquiring all shares of the company. The acquisition, which is subject to customary closing conditions, is expected to close on November 21, 2017. This acquisition allows Roche to expand its leading position in the Integrated Core Lab with business analytics capabilities, enabling laboratories to make faster data-driven informed decisions on their operations and processes. The cloud-based solution is secure, infrastructure-agnostic, interactive, and accessible from multiple devices (e.g. smart phones, tablets, desktop computers).

"We are excited that Viewics, Inc. will be joining the Roche Group, as it will help us to support our customers around the world in improving their lab performance and processes," said Roland Diggelmann, CEO Roche Diagnostics. "The Viewics solution offers our customers insights at their fingertips, uncovering potential value and profitability drivers in lab operations, and indicators to improve overall quality of care."

"We founded Viewics with the belief that unlocking the value of data would drive immense value for our customers. With Roche's expertise and strong alignment within our teams, we are excited to embark on this next phase of Viewics’ journey and jointly deliver on this mission," said Dhiren Bhatia, Founder and President of Viewics, Inc.

"Viewics, Inc. strives to provide unprecedented access to disparate healthcare data to surface actionable insights and empower data-driven decision-making," said Keith Laughman, CEO of Viewics, Inc. "The Viewics platform generates insights that can inform real-time decisions about costs, laboratory performance, and many other areas affecting today's modern healthcare organizations. We are looking forward to working with our Roche colleagues in helping to support the lab's critical role in healthcare delivery.

The Viewics solution offers automated data extraction, cleansing, and augmentation architecture and resolves many of the typical problems that laboratory IT staff encounter when using generic business intelligence solutions, traditional data warehousing, or extraction methodologies.

About Viewics, Inc.

Viewics, Inc. was founded in 2010 in Sunnyvale, CA (USA) and is an established market player in business analytics for laboratories. The company, headquartered in San Jose, CA, has employees across the U.S. and in its subsidiary in Pune, India.

Through expertise and focus on healthcare analytics, Viewics, Inc. delivers proprietary, best-in-class technology for data extraction, cleansing, and transformation that quickly unlock insights, which deliver invaluable operational and financial outcomes, while reducing burden on IT.

The HIPAA-compliant solution puts the transformational power of analytics into the hands of healthcare professionals in laboratory, financial, executive, and IT roles. The solution enables organizations to leverage insights out-of-the-box, combined with the flexibility of further customising the solution to meet the needs of their unique situations, truly interact with their data and make decisions based on accurate information to deliver significant impact.

About Roche

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry nine years in a row by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2016 employed more than 94,000 people worldwide. In 2016, Roche invested CHF 9.9 billion in R&D and posted sales of CHF 50.6 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

Most Popular Now

Forxiga receives positive EU CHMP opinion for the …

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended a new indication for the marketing authorisation of Forxi...

Merck Granted U.S. Patent for novel combination of…

Merck, a leading science and technology company, today announced that it has been granted Patent No. US 10,193,695 by the United States Patent and Trademark Office (USPTO...

Pfizer receives positive CHMP opinion for Vizimpro…

Pfizer today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending V...

US FDA grants Breakthrough Therapy Designation for…

AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Ther...

Merck to expand US biopharmaceutical R&D facil…

Merck, a leading science and technology company, today announced a $70 million investment to expand its state of the art research and development (R&D) facility in Biller...

Amgen and UCB receive positive vote from FDA Advis…

Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) announced strong support from the U.S. Food and Drug Administration (FDA) Bone, Reproductive and Urologic Drugs Advis...

New pill can deliver insulin

An MIT-led research team has developed a drug capsule that could be used to deliver oral doses of insulin, potentially replacing the injections that people with type 2 di...

Pfizer and Lilly announce top-line results from se…

Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced positive top-line results from a Phase 3 study evaluating tanezumab 2.5 mg or 5 mg in patients...

Merck and Tencent announce collaboration on intell…

Merck, a leading science and technology company, signed a strategic collaboration agreement with Tencent, a leading provider of Internet value added services. The collabo...

Cannabinoid compounds may inhibit growth of colon …

Medical marijuana has gained attention in recent years for its potential to relieve pain and short-term anxiety and depression. Now, Penn State College of Medicine resear...

Researchers call for big data infrastructure to su…

Researchers from the George Washington University (GW), the U.S. Food and Drug Administration (FDA), and industry leaders published in PLOS Biology, describing a standard...

New computational method reduces risk of drug form…

One major factor that determines the efficacy of a drug is the structure that its molecules form in a solid state. Changed molecular structures can entail that pills stop...